Sale of part of Agfa HealthCare’s IT business

·Sale to the Dedalus Group successfully closed in May, 2020 at an enterprise value of 975 million Euro

·Agfa HealthCare’s state-of-the-art Imaging IT software business is not included in the sale and will be a key source of future value creation for the Agfa-Gevaert Group


Financial highlights

·Solid results due to gross margin improvements and cost saving measures

·Radiology Solutions and HealthCare IT resilient

·Specific segments of printing industry started to be impacted by COVID-19

·Strong cash generation, driven by a substantial decrease in working capital – net financial debt decreased to 69 million Euro (excluding IFRS 16 impact)


Mortsel (Belgium), May 12, 2020 - Agfa-Gevaert today commented on its results in the first quarter of 2020.  

SALE OF PART OF AGFA HEALTHCARE’S IT BUSINESS
In May, the Agfa-Gevaert Group has successfully completed the sale of part of Agfa HealthCare’s IT business to the Dedalus Group at an enterprise value of 975 million Euro. The part that has been sold consists of the Healthcare Information Solutions activities (Electronic Health Record, the ORBIS platform) and the Integrated Care activities in Germany, Austria, Switzerland, France and Brazil as well as the Imaging IT activities to the extent that these activities are tightly integrated into the Healthcare Information Solutions activities in these geographies. In North America and all other international markets, Agfa HealthCare pursues its Imaging IT software business, which is not included in the sale.  

FINANCIAL HIGHLIGHTS
Thanks to its program to reduce working capital, the Agfa-Gevaert Group succeeded in generating strong cash flows in the first quarter of 2020. Excluding the impact of IFRS 16, net financial debt decreased to 69 million Euro.

On the one hand, the Radiology Solutions and HealthCare IT divisions showed resilience in the uncertain global economic conditions. Certain activities in the printing industry on the other hand, were starting to be impacted by the COVID-19 pandemic. This new challenge adds to the already tough conditions in this industry.
Thanks to gross margin improvements and cost saving measures, the Group was able to post strong results. Excluding the impact of the fading effects of the Siegwerk alliance in the Digital Print and Chemicals division, the Group’s adjusted EBITDA would have been in line with the first quarter of 2019.

“We feel deeply committed to our customers and the communities they serve. As many of our customers are operating in critical industries, we are taking all measures necessary to guarantee that we can continue supplying and supporting them during the COVID-19 pandemic. However, as always our utmost priority is protecting the health and safety of our employees. Furthermore, we are controlling our working capital levels, capital expenditure, and costs even more rigorously to mitigate as much as possible the impact of the pandemic on our liquidity and bottom-line result. As the printing industry – which was already under pressure – is being impacted by the pandemic, we are adapting our production capacity to the worsened market conditions, resorting to temporary unemployment where applicable.
Despite some impact of COVID-19 on our activities in the printing industry, we delivered a solid set of results and we generated strong cash flows. Our program to reduce working capital continues to be successful. It allowed us to further lower our net financial debt to a very healthy level,” said Pascal Juéry, President and CEO of the Agfa-Gevaert Group.

Statement on restated profit and loss numbers
As from 2019, the Agfa-Gevaert Group has adopted the IFRS 16 accounting rules. The tables below present the profit and loss numbers including the impact of IFRS 16.
In August 2019, the Group terminated its inkjet media reseller activities in the USA. To allow correct comparison, the Q1 2019 numbers have been restated.  


Agfa-Gevaert Group – Q1 2020

in million EuroQ1 2020

Q1 2019
Restated

% change
(excl.
FX effects)
Revenue501524-4.4% (-5.0%)
Gross profit (*)170172-1.0%
% of revenue33.9%32.7% 
Adjusted EBITDA (*)3943-9.7%
% of revenue7.8%8.2% 
Adjusted EBIT (*)1820-11.1%
% of revenue3.6%3.9% 

(*)     before restructuring and non-recurring items

The Agfa-Gevaert Group’s top line decreased by 4.4% due to the issues in the offset printing industry, the refocus on higher margin activities in several business areas and the first effects of the COVID-19 pandemic.

The Group’s gross profit margin improved from 32.7% of revenue in the first quarter of 2019 to 33.9% of revenue due to the above mentioned refocus on quality turnover and improved service and manufacturing efficiencies.

Selling and General Administration expenses decreased significantly from 22.6% of revenue in the first quarter of 2019 to 21.5%.

R&D expenses remained almost stable at 36 million Euro.

Due to the impact of the fading effects of the Siegwerk alliance, adjusted EBITDA decreased from 43 million Euro (8.2% of revenue) in the first quarter of 2019 to 39 million Euro (7.8% of revenue). Excluding the 4.5 million Euro Siegwerk impact, adjusted EBITDA would have been in line with last year. Adjusted EBIT reached 18 million Euro (3.6% of revenue), versus 20 million Euro (3.9% of revenue) in the first quarter of 2019.

Restructuring and non-recurring items resulted in an expense of 2 million Euro, versus an expense of 4 million Euro in the first quarter of 2019.

The net finance costs amounted to 8 million Euro.
                   
Income tax expenses amounted to 8 million Euro, versus 6 million Euro in the first quarter of 2019.

As a result of the elements mentioned above, the Agfa-Gevaert Group posted a net profit of 1 million Euro.

Financial position and cash flow

  • At the end of March 2020, total assets were 2,386 million Euro (comprising right-of-use assets compliant with the new accounting standard on leases: 107 million Euro at the end of March 2020), compared to 2,294 million Euro at the end of 2019.
  • Trade working capital decreased significantly from 579 million Euro (26% of sales) at the end of 2019 to 515 million Euro (23% of sales) at the end of March 2020.
  • Excluding the impact of IFRS 16, net financial debt decreased from 106 million Euro at the end of 2019 to 69 million Euro.
  • Net cash from operating activities amounted to 66 million Euro.

Outlook
It is impossible to predict how the COVID-19 pandemic will evolve and the timing of government decisions to ease restrictions is still very uncertain. Furthermore, it is currently unclear how strongly the Agfa-Gevaert Group’s various markets will be affected. However, in the coming quarters a significant COVID-19 impact on the printing industry is to be expected. Today’s situation does not allow the Group to assess a quantified impact of the pandemic on its 2020 financial performance and to provide a full year outlook for 2020. Management intends to give more guidance when it reports the second quarter results in August 2020.


HealthCare IT – Q1 2020

in million EuroQ1 2020

Q1 2019



 
% change
(excl.
FX effects)
Revenue122122-0.4% (-1.0%)
Adjusted EBITDA (*)19.715.626.1%
% of revenue16.1%12.8% 
Adjusted EBIT (*)12.78.845.6%
% of revenue10.5%7.2% 

(*)     before restructuring and non-recurring items

The HealthCare IT division’s top line remained stable compared to the first quarter of 2019. The gross profit margin improved from 45.4% of revenue in the first quarter of 2019 to 48.2%. Significant service efficiency improvements, and the decision to refocus the Imaging IT Solutions business had a positive effect on profitability. Adjusted EBITDA increased from 15.6 million Euro (12.8% of revenue) in the first quarter of 2019 to 19.7 million Euro (16.1% of revenue). Adjusted EBIT reached 12.7 million Euro (10.5% of revenue), versus 8.8 million Euro (7.2% of revenue) in the previous year.

For the Imaging IT Solutions business that is not included in the sale to the Dedalus Group, the division continues to execute its successful plan to improve profitability by focusing on generating ‘quality turnover’ in selected geographies and segments. As a result, this business posted a significant increase in margins versus the previous year. However, as some hospitals are now postponing investments in comprehensive software solutions, there is a risk that a COVID-19 impact will become visible in the next quarters.

The HealthCare IT division is deeply committed to support care providers and the communities they serve, in addressing current COVID-19 challenges. Under the hashtag #StrongerTogether, the division shares how its customers are making use of its software to efficiently triage, report and collaborate on COVID-19 cases.
In addition, specific configurations are being designed together with care providers. Those are subsequently published on the division’s website, so that others can benefit as well.

Radiology Solutions – Q1 2020

in million EuroQ1 2020

Q1 2019



 
% change
(excl.
FX effects)
Revenue1181171.3% (0.4%)
Adjusted EBITDA (*)16.417.1-4.3%
% of revenue13.9%14.7% 
Adjusted EBIT (*)10.111.5-12.0%
% of revenue8.5%9.8% 

(*)     before restructuring and non-recurring items

In the Radiology Solutions division, the Direct Radiography range posted strong revenue growth. Due to the COVID-19 outbreak, many hospitals are speeding up their investments in mobile Direct Radiography solutions. These devices can be used to perform high-quality bed-side X-ray examinations, even in intensive care units.
The top line of the Computed Radiography range continued to decline. This is partly market-driven and partly due to COVID-19 related effects, as private practices in India, Latin America and other geographies are postponing their investments in CR equipment.
The hardcopy product range posted a limited revenue decrease, which is entirely due to the impact of COVID-19 on the activities in China and India. Due to the outbreak, hospital visits not related to COVID-19 were postponed, resulting in a lower demand for hardcopy film.

Partly due to improved service efficiencies, the division’s gross profit margin increased from 36.5% of revenue in the first quarter of 2019 to 38.2%. Mainly due to adverse currency effects, adjusted EBITDA decreased from 17.1 million Euro (14.7% of revenue) in the first quarter of 2019 to 16.4 million Euro (13.9% of revenue). Adjusted EBIT reached 10.1 million Euro (8.5% of revenue), versus 11.5 million Euro (9.8% of revenue) in the previous year.

Since Radiology Solutions delivers products and solutions that are critical to hospitals in their fight against COVID-19, the division’s main focus is to ensure business continuity and to make sure that customers can continue to count on the knowhow of the service teams. Furthermore, the division supports hospitals all over the world with extra services, such as free software tools that help them to get faster and more accurate X-ray images. Examples on how Agfa and its employees support care providers in their battle against COVID-19 can be found in the dedicated #CountOnUs section of the division’s website.

Digital Print & Chemicals – Q1 2020

in million EuroQ1 2020

Q1 2019
Restated

 
% change
(excl.
FX effects)
Revenue74.386.6-14.2% (-14.5%)
Adjusted EBITDA (*)3.511.4-69.1%
% of revenue4.7%13.1% 
Adjusted EBIT (*)0.98.5-89.6%
% of revenue1.2%9.9% 

(*)     before restructuring and non-recurring items

In August 2019, the Group terminated its inkjet media reseller activities in the USA. To allow correct comparison, the Q1 2019 numbers have been restated. Other scope changes – such as the fade-out of the effects of the strategic alliance for UV digital packaging inks with Siegwerk Druckfarben – also influenced the division’s top line.

In inkjet, the ink product ranges performed well. On the other hand, many companies are postponing investments in high-end large-format printing equipment due to the COVID-19 pandemic. As this market almost came to a standstill in March, a strong COVID-19 impact will also be visible in the coming quarters.
In spite of these adverse conditions, Agfa still considers inkjet as an important growth engine. The company continues to explore promising business opportunities in new market segments. In the first quarter, Agfa entered into a strategic partnership with TFL for the development of Alussa, a dedicated inkjet printing solution to decorate high-quality genuine leathers used by the fashion, upholstery, automotive, aviation and nautical industries. Furthermore, Agfa introduced the Oberon RTR3300, a dedicated 3.3m high-end roll-to-roll machine that combines extreme productivity and quality with an extensive media scope and a unique ease of use.

The Industrial Films and Foils segment started to feel a limited COVID-19 impact due to the slowdown in industrial activities, whereas the businesses in the Electronic Print segment resisted well in the first quarter.

The division’s gross profit margin improved slightly from 29.4% of revenue in the first quarter of 2019 to 29.5%. Aside from COVID-19 related elements, the fade-out of the effects of the strategic alliance for UV digital packaging inks with Siegwerk Druckfarben had a 4.5 million Euro impact on the division’s results. The division’s adjusted EBITDA reached 3.5 million Euro (4.7% of revenue), versus 11.4 million Euro (13.1% of revenue) in the first quarter of 2019. Adjusted EBIT amounted to 0.9 million Euro (1.2% of revenue), versus 8.5 million Euro (9.9% of revenue).

Offset Solutions – Q1 2020

in million EuroQ1 2020

Q1 2019

 
% change
(excl.
FX effects)
Revenue187199-5.8% (-6.4%)
Adjusted EBITDA (*)3.73.9-5.2%
% of revenue2.0%2.0% 
Adjusted EBIT (*)(1.4)(3.6) 
% of revenue(0.7%)(1.8%) 

(*)     before restructuring and non-recurring items

The Offset Solutions division’s revenue decreased by 5.8% to 187 million Euro. The sales coming from the alliance with Lucky HuaGuang Graphics were not able to compensate for the structural decline of the offset markets and the effects of COVID-19 pandemic, which in the first quarter had an impact on the business in China. The pandemic causes a decrease in advertising and commercial activities, which in the coming quarters will lead to lower print volumes and a lower demand for printing plates.

The Offset Solutions division’s gross profit margin decreased slightly from 24.1% of revenue in the first quarter of 2019 to 23.6%. Due to improved manufacturing efficiencies and savings on operating expenditures, adjusted EBIT improved to minus 1.4 million Euro (minus 0.7% of revenue), from minus 3.6 million Euro (minus 1.8% of revenue) in the first quarter of 2019. Adjusted EBITDA remained almost stable at 3.7 million Euro (2.0% of revenue).

The Offset Solutions division has implemented cost containment plans, working capital measures and other actions to improve profitability and to adapt its activities to the worsened market situation. In the first quarter, the division temporarily stopped the production of printing plates in its plants in Leeds (UK) and Pont-à-Marcq (France) to address the impact of the COVID-19 pandemic. The production activities in the Wiesbaden plant (Germany) have also been temporarily scaled back.

Corporate Services – Q1 2020

in million EuroQ1 2020

Q1 2019

 
Adjusted EBITDA (*)(4.3)(4.8)
Adjusted EBIT (*)(4.3)(4.9)

(*)     before restructuring and non-recurring items

End of message
Management Certification of Financial Statements and Quarterly Report
This statement is made in order to comply with new European transparency regulation enforced by the Belgian Royal Decree of November 14, 2007 and in effect as of 2008.
"The Board of Directors and the Executive Committee of Agfa-Gevaert NV, represented by Mr. Klaus Röhrig, Chairman of the Board of Directors, Mr. Pascal Juéry, President and CEO, and Mr. Dirk De Man, CFO, jointly certify that, to the best of their knowledge, the consolidated financial statements included in the report and based on the relevant accounting standards, fairly present in all material respects the financial condition and results of Agfa-Gevaert NV, including its consolidated subsidiaries. Based on our knowledge, the report includes all information that is required to be included in such document and does not omit to state all necessary material facts.”

Statement of risk
This statement is made in order to comply with new European transparency regulation enforced by the Belgian Royal Decree of November 14, 2007 and in effect as of 2008.
"As with any company, Agfa is continually confronted with – but not exclusively - a number of market and competition risks or more specific risks related to the cost of raw materials, product liability, environmental matters, proprietary technology or litigation."
Key risk management data is provided in the annual report available on www.agfa.com.

Contact:
Viviane Dictus
Director Corporate Communication
Septestraat 27
2640 Mortsel - Belgium
T +32 (0) 3 444 71 24
E viviane.dictus@agfa.com

Johan Jacobs
Corporate Press Relations Manager
T +32 (0)3/444 80 15
E johan.jacobs@agfa.com

The full press release and financial information is also available on the company's website: www.agfa.com


Consolidated Statement of Profit or Loss (in million Euro)

Consolidated figures following IFRS accounting policies.

 Q1 2020

 
Q1 2019
Restated
Continuing operations  
Revenue501524
Cost of sales(332)(352)
Gross profit170172
Selling expenses(70)(76)
Administrative expenses(41)(44)
R&D expenses(36)(37)
Net impairment loss on trade and other receivables, including contract assets(2)(1)
Other operating income614
Other operating expenses(11)(12)
Results from operating activities1616
Interest income (expense) - net(2)(2)
Interest income--
Interest expense(2)(3)
Other finance income (expense) - net(7)(8)
Other finance income32
Other finance expense(9)(11)
Net finance costs(8)(11)
Share of profit of associates, net of tax--
Profit (loss) before income taxes75
Income tax expenses(6)(8)
Profit from continuing operations1(3)
Profit (loss) from discontinued operation, net of tax-(1)
Profit (loss) for the period1(3)
Profit (loss) attributable to:  
  Owners of the Company2(4)
  Non-controlling interests--
   
Results from operating activities1616
Restructuring and non-recurring items(2)(4)
Adjusted EBIT1820
   
Earnings per share (Euro)0.01(0.02)



Consolidated Statements of Comprehensive Income for quarter ending March 2019 / March 2020 (in million Euro) 
Consolidated figures following IFRS accounting policies

 Q1 2020

 
Q1 2019
Profit / (loss) for the period1(3)
Other Comprehensive Income, net of tax  
Items that are or may be reclassified subsequently to profit or loss:  
Exchange differences:(17)10
  Exchange differences on translation of foreign operations(17)10
Cash flow hedges: (3)5
  Effective portion of changes in fair value of cash flow hedges(6)1
  Changes in the fair value of cash flow hedges reclassified to profit or loss-1
Adjustments for amounts transferred to initial carrying amount of hedged items22
  Income taxes--
Items that will not be reclassified subsequently to profit or loss:(3)1
Equity investments at fair value through OCI – change in fair value(2)1
Remeasurements of the net defined benefit liability(1)-
Income tax on remeasurements of the net defined benefit liability--
Total other Comprehensive Income for the period, net of tax(23)15
   
Total Comprehensive Income for the period attributable to:(21)12
Owners of the Company(21)10
Non-controlling interests-2



Consolidated Statement of Financial Position (in million Euro)

Consolidated figures following IFRS accounting policies.

 

 
31/03/2020

 
31/12/2019

 
Non-current assets1,0481,060
Goodwill488492
Intangible assets7274
Property, plant & equipment140142
Right-of-use assets107110
Investments in associates34
Other financial assets58
Trade receivables 1821
Receivables under finance leases 6862
Other assets2224
Deferred tax assets125125
Current assets1,3371,234
Inventories469436
Trade receivables384408
Contract assets107100
Current income tax assets6875
Other tax receivables2325
Receivables under finance lease 2634
Other receivables2415
Other assets2721
Derivative financial instruments 41
Cash and cash equivalents195107
Non-current assets held for sale1010
TOTAL ASSETS2,3862,294



 

 
31/03/2020

 
31/12/2019

 
Total equity109130
Equity attributable to owners of the company6283
Share capital187187
Share premium210210
Retained earnings805803
Reserves(89)(84)
Translation reserve(22)(5)
Post-employment benefits: remeasurements of the net defined benefit liability(1,029)(1,028)
Non-controlling interests4747
Non-current liabilities1,4421,402
Liabilities for post-employment and long-term termination benefit plans1,1291,137
Other employee benefits1212
Loans and borrowings274225
Provisions55
Deferred tax liabilities1719
Trade payables22
Contract liabilities -1
Other non-current liabilities11
Current liabilities835761
Loans and borrowings98101
Provisions3745
Trade payables272232
Contract liabilities189151
Current income tax liabilities5349
Other tax liabilities2538
Other payables89
Employee benefits145130
Other current liabilities21
Derivative financial instruments75
TOTAL EQUITY AND LIABILITIES2,3862,294



Consolidated Statement of Cash Flows (in million Euro) Consolidated figures following IFRS accounting policies.

 Q1 2020

Q1 2019

 
Profit (loss) for the period1(3)
Income taxes68
Share of (profit)/loss of associates, net of tax--
Net finance costs811
Operating result1615
Depreciation & amortization (excluding D&A on right-of-use assets)1214
Depreciation & amortization on right-of-use assets99
Impairment losses on right-of-use assets(1)3
Exchange results and changes in fair value of derivates-4
Recycling of hedge reserve-1
Government grants and subsidies(3)(3)
(Gains)/losses on the sale of intangible assets and PP&E and remeasurement of leases--
Expenses for defined benefit plans & long-term termination benefits87
Accrued expenses for personnel commitments2626
Write-downs/reversal of write-downs on inventories43
Impairments/reversal of impairments on receivables21
Additions/reversals of provisions-(2)
Other non-cash expenses3738
Change in inventories(39)(38)
Change in trade receivables1818
Change in contract assets(9)(4)
Change in trade working capital assets(29)(23)
Change in trade payables4412
Change in contract liabilities3926
Changes in trade working capital liabilities 8238
Changes in trade working capital5315
Cash out for employee benefits(27)(41)
Cash out for provisions(9)(8)
Changes in lease portfolio2-
Changes in other working capital(26)(5)
Cash settled operating derivatives(3)(4)
Cash generated from operating activities6337
Income taxes paid3(3)
Net cash from / (used in) operating activities6634



 Q1 2020

Q1 2019

 
Capital expenditure(8)(8)
Proceeds from sale of intangible assets and PP&E11
Acquisition of subsidiaries, net of cash acquired-(7)
Interests received11
Dividends received--
Net cash from / (used in) investing activities(7)(14)
Interests paid(3)(3)
Proceeds from borrowings571
Repayment of borrowings(1)(67)
Payment of finance leases(10)(10)
Changes in borrowings45(76)
Proceeds / (payment) of derivatives(2)2
Other financing income / (costs) incurred(1)(1)
Other financial flows1-
Net cash from/ used in financing activities41(78)
Net increase / (decrease) in cash & cash equivalents100(57)
   
Cash & cash equivalents at the start of the period99136
Net increase / (decrease) in cash & cash equivalents100(57)
Effect of exchange rate fluctuations on cash held(9)(2)
Cash & cash equivalents at the end of the period19077



ATTRIBUTABLE TO OWNERS OF THE COMPANY  

 


in million Euro
Share capitalShare premiumRetained earningsReserve for own sharesRevaluation reserve Hedging reserveRemeasurements of the net defined benefit liabilityTranslation reserveTotalNON-CONTROLLING INTERESTSTOTAL EQUITY
 

Balance at January 1, 2019
187210854(82)1(12)(897)(9)25238290
            
Comprehensive income for the period           
Profit (loss) for the period--(4)-----(4)-(3)
Other comprehensive income, net of tax----15-914115
Total comprehensive income for the period--(4)-15-910212
            
Transactions with owners, recorded directly in equity           
Dividends-----------
Total transactions with owners, recorded directly in equity-----------
            
Balance at March 31, 2019187210851(82)2(8)(897)-26240303
            
Balance at January 1, 2020187210803(82)1(3)(1,028)(5)8347130
            
Comprehensive income for the period           
Profit (loss) for the period--2-----2-1
Other comprehensive income, net of tax----(2)(3)(1)(17)(23)-(23)
Total comprehensive income for the period--2-(2)(3)(1)(17)(21)-(21)
            
Transactions with owners, recorded directly in equity            
Dividends-----------
Total transactions with owners, recorded directly in equity-----------
            
Balance at March 31, 2020187210805(82)(1)(6)(1,029)(22)6247109

Attachments